Loading clinical trials...

RECRUITINGNA

Carbon Dioxide Laser vs. Electrocoagulation for the Therapy of Condyloma

Carbon Dioxide Laser Ablation Versus Electrocoagulation - a Prospective, Randomized Multicenter Trial Comparing Two Surgical Treatments in Women Undergoing Therapy for Condyloma Acuminata

NCT02520986•Zydolab - Institute of Cytology and Immune Cytochemistry

View on ClinicalTrials.gov

Summary

In a randomized clinical trial of 114 women undergoing Treatment for condyloma acuminata, two surgical methods, the carbon dioxide laser Ablation and the excision by electrocoagulation, will be compared. The primary outcome of the study is the cosmetic result judged by the Patient 6 weeks after Treatment using a 11-step visual analogue scale (VAS), secondary outcomes are intervention time, operative complications, subjects and users satisfaction, postoperative pain and recurrence of genital warts.

Eligibility

Age

18 - No limit years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•informed consent
•women with anogenital affection of condyloma acuminata

Exclusion Criteria

•significant language barrier
•pregnancy
•unwillingness to participate
•the use of blood thinner or known coagulation disorder
•the use of immunosuppressive medicament
•HIV-Infection
•malignant diseases
•local therapy within 8 weeks before Treatment
•wound healing disorder

Locations (1)

Department of Obstetrics and Gynecology of the Ruhr University Bochum

Herne, North Rhine-Westphalia, Germany

Key Dates

Start Date

December 1, 2016

Primary Completion Date

December 1, 2026

Completion Date

December 1, 2026

Last Updated

August 19, 2025

Enrollment

114

ESTIMATED participants

Conditions

Condylomata Acuminata

Interventions

Carbon dioxide Laser ablation

DEVICE

Electrocoagulation

DEVICE

Contacts

Ziad Hilal, Dr. med.

CONTACT

+49231529747 z.hilal@zydolab.de

Immunogenicity Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)

NCT03935204

Condylomata AcuminataCervical Cancer

View study

COMPLETEDPHASE3

Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)

NCT03546842

Papillomavirus InfectionsUterine Cervical Neoplasms+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 19, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Carbon Dioxide Laser vs. Electrocoagulation for the Therapy of Condyloma

Inclusion Criteria

Exclusion Criteria

Immunogenicity Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)

Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)

Efficacy and Safety Profiles of SR-T100 Gel on External Genital Warts/Condyloma Acuminate(EGWs)

Efficacy of Intralesional MMR Vaccine,Intralesional Candidal Antigen&Topical Podophyllin in Treatment of Genital Warts

Safety and Efficacy Study of Topical Ranpirnase to Treat Genital Warts (HPV)

Safety and Efficacy of Immune Therapy for Condyloma